Skip to main content

Table 1 Baseline demographics

From: Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first- or second-line treatment of patients with metastatic triple-negative breast cancer

  Cohort 1 Cohort 2 Overall
  (n = 9) (n = 10) (n = 19)
Mean age, years (range) 50.0 (36 to 71) 50.7 (38 to 67) 50.4 (36 to 71)
ECOG status, n    
0/1/2 8/1/0 5/5/0 13/6/0
Previous chemotherapy regimens, n (%)    
 Any adjuvant regimen 5 (56) 9 (90) 14 (74)
 Taxanea 7 (78) 8 (80) 15 (79)
  First-line setting 2 (22) 0 2 (11)
  Adjuvant setting 2 (22) 6 (60) 8 (42)
  Neo-adjuvant setting 3 (33) 1 (10) 4 (21)
  Metastatic setting 0 2 (20) 2 (11)
 Anthracycline 6 (67) 6 (60) 12 (63)
 Capecitabine 1 (11) 0 1 (5)
  1. ECOG, Eastern Cooperative Group.
  2. aOne patient in cohort 2 had previously received taxane chemotherapy in both adjuvant and metastatic settings.